1 **Title** 2 Health Utility Value of Overactive Bladder in Japanese Older Adults 3 4 **Authors and affiliations** Takashi Yoshioka, MD, PhD 1,2* 5 Kenji Omae, MD, DrPH ^{3,4} 6 Satoshi Funada, MD, PhD 1 7 Tetsuji Minami, MD, PhD⁵ 8 Rei Goto, MD, PhD ^{6,7} 9 10 ¹ Health Technology Assessment Unit, Department of Preventive Medicine and Public Health, 11 12 Keio University School of Medicine, Tokyo, Japan 13 ² Institute of Clinical Epidemiology, Showa University, Tokyo, Japan ³ Department of Innovative Research and Education for Clinicians and Trainees (DiRECT), 14 15 Fukushima Medical University Hospital, Fukushima, Japan 16 ⁴ Department of Health Promotion and Human Behavior, Graduate School of 17 Medicine/School of Public Health, Kyoto University, Kyoto, Japan 18 ⁵ Division of Quality Assurance Programs, Institute for Cancer Control, National Cancer 19 Center, Tokyo, Japan 20 ⁶ Graduate School of Health Management, Keio University, Kanagawa, Japan 21 ⁷ Graduate School of Business Administration, Keio University, Kanagawa, Japan 22 23 *Corresponding author 24 Takashi Yoshioka 25 Health Technology Assessment Unit, Department of Preventive Medicine and Public Health, 26 Keio University School of Medicine, Tokyo, Japan 27 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan 28 Tel:+81-3-5363-3205 29 E-mail: ty5733@keio.jp

30 31 E-mail address: 32 Takashi Yoshioka, ty5733@keio.jp 33 Kenji Omae, oranz416@gmail.com 34 Satoshi Funada, sfunada@keio.jp 35 Tetsuji Minami, t.minami.for.urology@gmail.com 36 Rei Goto, reigoto@kbs.keio.ac.jp 37 38 Word counts: 3,324 39 **Number of Tables:** 3 40 **Number of Figures:** 3 41 **Number of References: 30**

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64 65 3

Abstract **Objectives:** To determine the health utility values (HUVs) of overactive bladder (OAB) among adults aged ≥65 years and to assess the HUV decrements (disutilities) of OAB according to its severity. **Methods:** This cross-sectional Internet-based study was conducted between 2 and 9 November 2023, with quota sampling with equal probability for each gender and age group (age 65–74 years and \geq 75 years). OAB was defined as an urgency score of \geq 2 points and a total score of ≥3 points based on the Overactive Bladder Symptom Score. OAB severity was categorized as mild (total score, \leq 5 points) or moderate-to-severe (total score, 6–15 points). HUVs were measured using the EuroQol 5-Dimension 5-Level value set for the Japanese population. Multivariable linear regression models were fitted to estimate the covariate-adjusted disutilities of OAB, with eight covariates selected based on previous studies. **Results:** Among the 998 participants (51.9% male; median age, 75 years), 158 (15.9%) had OAB, of whom 87 (8.8%) had moderate-to-severe OAB. The mean HUVs for participants with mild and moderate-to-severe OAB were 0.874 and 0.840, respectively, which were lower compared with the HUV for those without OAB (0.913). After adjusting for relevant covariates, disutilities (95% confidence intervals [CIs]) for mild and moderate-to-severe OAB were -0.0334 (-0.0602 to -0.0066) and -0.0591 (-0.0844 to -0.0339), respectively. **Conclusions:** This study examined HUVs in older Japanese adults with and without OAB. The results demonstrate that increased OAB severity is associated with greater disutility.

66 Keywords:

69

- Overactive bladder; lower urinary tract symptoms; health utility; health-related quality of life;
- 68 health economic evaluation

Introduction

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

Overactive bladder (OAB), characterized by urinary urgency with or without urgent urinary incontinence, is associated with a substantial disease burden and significant economic impact [1]. The extensive disease burden of OAB includes a decrease in health-related quality of life (HRQoL), mood disorders, and various comorbid or consequential conditions (e.g. constipation, fecal incontinence, and irritable bowel syndrome) [2]. The prevalence of OAB increases with age [3]. Furthermore, evidence has demonstrated a longitudinal association between OAB or its treatment with anticholinergics and an increased risk of falls, which are the most critical outcomes in older adults [4]. Consequently, patients with OAB have higher healthcare resource utilization than those without the condition, which contributes to a substantial economic burden [5]. The high global prevalence of OAB, estimated at 15.5% between 2007 and 2020, and its high healthcare cost of \$82.6 billion by 2020 in the United States [1, 6] have drawn significant attention from both policymakers and clinicians worldwide. OAB is widely managed in various healthcare settings, including primary care, urology, and urogynecology [7]. Treatment options for OAB include behavioral therapy and pharmacotherapy, such as antimuscarinic and β-adrenergic agents [7]. Surgical treatments are available for refractory cases, including intradetrusor injection of onabotulinum toxin A, sacral neuromodulation, and percutaneous tibial nerve stimulation [7]. Although these therapeutic options have the potential to relieve patients' symptoms and improve their HRQoL, they also raise concerns about the increasing economic burden on healthcare systems owing to higher treatment costs. Consequently, the importance of effectively allocating finite healthcare resources for the management of OAB is becoming increasingly recognized. In fact, the National Institute for Health and Care Excellence (NICE), an independent organization providing evidence-based guidance to inform healthcare decisions in the United Kingdom (UK), is currently conducting a health economic evaluation (HEE) of vibegron [8], a novel β3-adrenergic agonist with fewer antimuscarinic side effects compared

with traditional OAB medications [9]. Considering the example of the NICE in the UK, new

medical technologies for OAB, such as vibegrons, may also be subject to HEEs in other countries, such as Japan.

To make HEEs useful for policy decision-making, it is essential to assess their clinical effectiveness (e.g. quality-adjusted life years [QALYs]) using generic measures that can be collected for any disease. QALYs are calculated based on health utility values (HUVs) measured using generic preference-based measures (PBMs) rather than disease-specific ones [10]. Importantly, according to the NICE technology appraisal guidance, HUVs should be calculated using the EuroQoL 5-dimensions (EQ-5D), with data collected directly from patients in the country where the evaluation is being conducted (in the case of NICE, the UK) [11]. Previous studies have evaluated the association between OAB symptoms and HUVs using EQ-5D scores in the United States, United Kingdom, Spain, and South Korea [12–14]. However, these studies have utilized the older version of the EQ-5D, the three-level EQ-5D version (EQ-5D-3L), which raises concerns about the potential overestimation of positive effects and underestimation of negative effects [15]. The newer version of the EQ-5D, the five-level EQ-5D version (EQ-5D-5L), was developed to overcome the ceiling effects and low sensitivity inherent in EQ-5D-3L [16]. Ideally, the estimation of HUVs based on EQ-5D-5L is essential. However, few studies have used this instrument. To address the unmet needs of global policies regarding HEEs of OAB, this study aimed to describe the HUVs of patients with OAB and assess the impacts of OAB on HUVs using EQ-5D-5L among older adults, the most vulnerable and policy-relevant subgroup,

Participants and methods

using an Internet-based survey.

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

Study design and participants

This cross-sectional study was conducted as part of a research project aimed at developing an EQ-5D-5L value set for the Japanese general older adults [16]. To obtain responses from a sample of older adults, we used a sampling method that ensured a 1:1 ratio for both sex and age groups (age 65–74 and \geq 75 years). The target sample size was 1,000 participants. The sampling strategy and sample size were determined based on a previous study [17]. All

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

8

(never/past/current), and self-reported coexisting physical and psychiatric comorbidities.

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

9

1975 Declaration of Helsinki and its subsequent 2013 revision. This study was approved by

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

10

-0.0339; p<0.001), respectively, indicating a linear relationship (p for trend<0.001). The

sensitivity analysis using the EQ VAS as the outcome variable showed similar results

244 (presence of OAB, $\beta = -5.42$, 95% CI -8.47 to -2.37, p = 0.001; mild OAB, $\beta = -4.36$, 95% CI 245 -8.60 to -0.12, p=0.044; moderate-to-severe OAB, $\beta=-6.26$, 95% CI -10.26 to -2.27, 246 p=0.002; p for trend<0.001). 247 248 Results of the subgroup analysis 249 **Tables S1** and **S2** present the baseline characteristics of the sex and age subgroups, 250 respectively. Table S3 summarizes the HUVs for sex and age subgroups of HUVs. In the sex 251 subgroup, regardless of the presence of OAB, women (n=478) had lower mean HUVs than 252 men (n=516) (e.g. presence of any OAB: men, 0.872 [SD, 0.128]; women, 0.821 [SD, 0.173]). 253 In the age subgroup, regardless of the presence of OAB, the 75–94-year-old group (n=502) 254 showed lower HUVs compared with the 65–74-year-old group (n=492) (e.g. presence of any 255 OAB: 65–74 years old, 0.889 [SD, 0.130]; 75–94 years old, 0.829 [SD, 0.152]). 256 The results of the multivariable linear regression analysis are shown in **Figure 2**. In 257 the sex subgroup, a substantial disutility was observed in women with moderate-to-severe 258 OAB (β =-0.1026; 95% CI, -0.1510 to -0.0542; p<0.001). In the age subgroup, substantial 259 disutilities were observed in the 75–94-year-old group with mild OAB (β =-0.0688; 95% CI, 260 -0.1106 to -0.0271; p=0.001) and moderate-to-severe OAB (β =-0.0664; 95% CI, -0.1006 to 261 -0.0322; p<0.001). 262 263 Results of the exploratory analysis 264 **Table S4** presents a summary of the HUVs for each domain and the score of the OABSS. 265 The higher OABSS scores indicated the lower mean HUVs in the three domains, excluding 266 urgency urinary incontinence. The results of the multivariable linear regression analysis after 267 rounding scores of <2.5% of the total are shown in **Figure 3**. After adjusting for covariates, 268 disutilities were observed for each score in the three domains, excluding daytime frequency 269 (e.g. nighttime frequency: 1 point, $\beta = -0.0089$, 95% CI -0.0276 to 0.0099, p = 0.035; 2 points, 270 β =-0.0193, 95% CI -0.0411 to 0.0025, p=0.082; 3 points, β =-0.0409, 95% CI -0.0682 to 271 -0.0136, p=0.003). A linear relationship between scores and disutilities was observed in all

domains, except for daytime frequency (p for trend: nighttime frequency, 0.003; urgency, <0.001; and urgency incontinence, <0.001).

Discussion

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

This study described the HUVs of Japanese adults aged ≥65 years with or without OAB and estimated the associated disutility of OAB using regression models. The results demonstrated that the mean HUVs of individuals with OAB were lower and the disutility of OAB was greater, depending on the severity of the condition. Subgroup analyses suggested that women and those aged 75 years might experience greater disutility owing to OAB than their counterparts. Furthermore, exploratory analyses indicated the possibility of score-proportional disutility in all domains of the OABSS, except daytime frequency.

Previous studies have evaluated the associations of OAB with HUVs in several countries. Kay et al. conducted a study estimating EQ-5D-3L-based HUVs from the Incontinence-Specific Quality of Life Questionnaire in 2,505 patients with idiopathic or neurogenic OAB in the United States and Europe [12]. Similarly, Ruiz et al. used the Overactive Bladder Symptom and Health-Related Quality of Life Questionnaire in 246 patients with OAB to estimate the effects of OAB symptoms on EQ-5D-3L-based HUVs in Spain [13]. Additionally, Kim et al. assessed the effects of OAB severity as defined by the OABSS on EQ-5D-3L-based HUVs in 226,867 participants (including 12,303 patients with OAB) from the 2012 Korean Community Health Survey [14]. These studies shared two common features. First, they estimated the associations of OAB with HUVs using OAB measures that are policy-relevant in their respective countries. Second, they employed the EQ-5D-3L for evaluation. These factors significantly influenced the design of this study in a Japanese setting. Second, regarding the choice of OAB measure, we used the OABSS, similar to Kim et al., as it is explicitly used to define OAB in the Japanese OAB guidelines [23]. The OABSS was used to define OAB in a randomized controlled trial evaluating the effects of OAB interventions in Japan [24]. Therefore, decision modelling based on the OABSS is expected when conducting HEEs targeting patients with OAB in Japan. Second, we used the

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

EQ-5D-5L, for which a value set developed and validated by Ikeda et al. exists in Japan [17]. Evidence suggests that the EQ-5D-3L may potentially overestimate positive associations and underestimate negative associations compared with the EQ-5D-5L in HEEs [15]. Consequently, the EO-5D-5L is recommended for cost-effectiveness evaluations in Japan [25], and our study adhered to this recommendation. This study, which fully considers Japanese clinical practices and healthcare systems, provides HUVs appropriate for HEEs in the Japanese setting. We believe that our approach offers valuable insights for the design of future studies in any country. In this study, the disutility values for mild and moderate-to-severe OABs as defined by the OABSS were -0.034 and -0.0591, respectively. When referring to the Japanese population norms using the EQ-5D-5L, these disutilities are comparable to those of other chronic conditions that affect HRQoL, such as allergic rhinitis (-0.027), atopic dermatitis (-0.031), and other skin diseases (-0.043) [26]. In a report from Korea, which used the same scale (OABSS) and criteria to define OAB as our study, the covariate-adjusted disutility values for mild OAB, moderate OAB, and severe OAB were -0.029, -0.089, and -0.179, respectively [14]. The smaller disutility for moderate-to-severe OAB in our study compared to Kim et al.'s findings may be explained by differences in the mean age (75 years vs. 45.2) years), outcome measure (EQ-5D-5L vs. EQ-5D-3L), and ethnicity (Japanese vs. Korean). However, both studies consistently showed that disutility increased with severity, emphasizing the importance of the associations of OAB with HUVs. Furthermore, our study found high disutility (-0.1026) among female participants with moderate-to-severe OAB in the subgroup analyses. This finding may be supported by the results of EpiLUTS, an Internet survey conducted among individuals aged >40 years in the United States, which showed that a higher proportion of women (39.4%) than men (28.7%) reported moderate-to-severe problems in their patient perception of bladder condition for OAB with bother [27]. Additionally, in the subgroup of individuals aged ≥75 years, mild and moderate-to-severe OABs were associated with disutility values of similar magnitude (mild OAB -0.0688 vs. moderate-to-severe OAB –0.0664). This finding suggests that the presence of OAB,

regardless of severity, may have a substantial impact on older adults who are more likely to

be frail than younger respondents. For example, evidence has shown that even in the absence of incontinence, the presence of OAB is a significant risk factor for falls [28].

Our study has several strengths. First, we comprehensively provided the descriptive and analytical information necessary for the HEE of OAB, specifically for older adults. The mean and median HUVs at baseline and the disutilities after covariate adjustment for each severity level of OAB are essential information when conducting HEEs. Second, this study estimated disutility by adjusting for a wide range of evidence-based covariates, from socioeconomic to health-related indicators. Third, a subgroup analysis was performed to identify vulnerable populations that are essential for HEEs from the perspective of equity considerations but are understudied [29]. Moreover, our subgroup analysis results provide HUVs that can be referenced in future HEEs, particularly when treatments specifically targeting nocturia or urgent urinary incontinence among the OAB symptoms become available.

However, this study has also some limitations. First, as this study utilized an Internet survey, there were concerns regarding the external validity of the results. However, the prevalence of OAB (15.9%) and mean HUV (0.89) in this study did not substantially differ from previous epidemiological data from Japan [26, 30]. Thus, these values are also expected to apply to HEEs. Second, the sample size was limited (approximately 1,000); consequently, there were few individuals with high scores on the OABSS (e.g. 2 points for daytime frequency and 4–5 points for urgency urinary incontinence). As a result, it was not possible to differentiate between moderate and severe OAB, and some scores were grouped in the exploratory analysis. Although the number of individuals with such high scores may not be large and may not be considered in actual HEEs, revalidation of our study with a larger sample size would be valuable. Third, there may have been residual confounding factors. For example, orthopedic factors, such as falls and fractures, can be considered in future models.

In conclusion, this study examined HUVs in older Japanese adults with and without OAB. The results also demonstrated that increasing the severity of OAB indicated greater disutility, highlighting the substantial effect of OAB on HRQoL. These findings serve as

valuable resources for future HEEs of OAB, possibly guiding decision-making in healthcare resource allocation for policymakers.

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

16

Acknowledgments This study was supported by the Japan Society for the Promotion of Science KAKENHI grant (grant number: 21K17228) for conducting the survey. This study was also supported by the National Institute of Public Health for the language editing fee and article publishing charge. **Conflicts of interest** TY has received the Japan Society for the Promotion of Science (JSPS) KAKENHI grant (grant number: 21K17228) for conducting the survey. RG has received grants for the evaluation of the cost-effectiveness of medicines and medical devices from the National Institute of Public Health, Japan since 2019, which support the consultation fees for the development of search strategies and will support the article publication fee. KO, SF, and TM have no conflicts of interest to declare. The funders did not participate in the study design, data collection, analysis, interpretation, manuscript preparation, review, approval, or decision to submit the manuscript for publication. **Data availability statement** The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.

References

- 381 1. Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and
- economic burden of urgency urinary incontinence: a systematic review. Eur Urol 2014;
- 383 65: 79–95.
- 2. Peyronnet B, Mironska E, Chapple C, et al. A comprehensive review of overactive bladder
- pathophysiology: on the way to tailored treatment. *Eur Urol* 2019; 75: 988–1000.
- 386 3. Eapen RS, Radomski SB. Review of the epidemiology of overactive bladder. Res Rep Urol
- 387 2016; 8: 71–6.
- 388 4. Just KS, Schultze KA, Dormann H, et al. Use of overactive bladder anticholinergic
- medications associated with falls leading to emergency department visits: results from
- 390 the ADRED study. *Eur J Clin Pharmacol* 2023; 79: 1185–93.
- 391 5. Durden E, Walker D, Gray S, Fowler R, Juneau P, Gooch K. The economic burden of
- overactive bladder (OAB) and its effects on the costs associated with other chronic,
- age-related comorbidities in the United States. *Neurourol Urodyn* 2018; 37: 1641–9.
- 6. Lin W, Li T, Xu Z, et al. Association of socioeconomic status and overactive bladder in
- 395 US adults: a cross-sectional analysis of nationally representative data. Front Public
- 396 *Health* 2024; 12: 1345866.
- 397 7. Raju R, Linder BJ. Evaluation and treatment of overactive bladder in women. Mayo Clin
- 398 *Proc* 2020; 95: 370–7.
- 8. Project information | Vibegron for treating symptoms of overactive bladder ID6300 |
- 400 Guidance | NICE. [cited 2024 Jun 5]. Available from:
- 401 https://www.nice.org.uk/guidance/indevelopment/gid-ta11348.
- 402 9. Keam SJ. Vibegron: first global approval. *Drugs* 2018; 78: 1835–9.
- 403 10. Chang EM, Saigal CS, Raldow AC. Explaining health state utility assessment. JAMA

- 404 2020; 323: 1085–6.
- 405 11. Foreword | Guide to the methods of technology appraisal, 2013. Guidance | NICE. [cited
- 406 2024 Jun 5]. Available from: https://www.nice.org.uk/process/pmg9/chapter/foreword.
- 407 12. Kay S, Tolley K, Colayco D, Khalaf K, Anderson P, Globe D. Mapping EQ-5D utility
- scores from the Incontinence Quality of Life Questionnaire among patients with
- neurogenic and idiopathic overactive bladder. *Value Health* 2013; 16: 394–402.
- 410 13. Ruiz MA, Gutiérrez LL, Monroy M, Rejas J. Mapping of the OAB-SF questionnaire onto
- 411 EQ-5D in Spanish patients with overactive bladder. *Clin Drug Investig* 2016; 36:
- 412 267–79.
- 413 14. Kim SK, Kim SH. The impact of overactive bladder on health-related quality of life in
- Korea: based on the results of a Korean Community Health Survey. *Qual Life Res* 2021;
- 415 30: 1017–24.
- 416 15. Wailoo A, Alava MH, Pudney S, et al. An international comparison of EQ-5D-5L and
- 417 EQ-5D-3L for use in cost-effectiveness analysis. *Value Health* 2021; 24: 568–74.
- 418 16. EuroQol [Internet], 2022 [cited 2024 Jun 10]. Available from:
- 419 https://euroqol.org/information-and-support/euroqol-instruments/eq-5d-5l/. Eq-5d-5l.
- 420 17. Ikeda S, Shiroiwa T, Igarashi A, et al. Developing a, Japanese version of the EQ-5D-5L
- 421 value set. J Natl Inst Public Health 2015; 64: 47–55.
- 422 18. Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder
- 423 syndrome--overactive bladder symptom score. *Urology* 2006; 68: 318–23.
- 424 19. Welk B, Baverstock R. Is there a link between back pain and urinary symptoms?
- 425 Neurourol Urodyn 2020; 39: 523–32.
- 426 20. Ceyhun G, Erbay G. Relationship between the severity of coronary artery disease and
- 427 overactive bladder. *Acta Cardiol Sin* 2021; 37: 254–60.

- 428 21. Lai S, Pastore S, Piloni L, et al. Chronic kidney disease and urological disorders:
- 429 systematic use of uroflowmetry in nephropathic patients. *Clin Kidney J* 2019; 12: 414–9.
- 430 22. Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome:
- evaluation and management. *Curr Urol* 2018; 11: 117–25.
- 432 23. The Japanese Continence Society, The Japanese Urological Association, eds. *Clinical*
- 433 Guidelines for Overactive Bladder Syndrome, 3rd edn, 2022.
- 434 24. Funada S, Luo Y, Uozumi R, et al. Multicomponent intervention for overactive bladder in
- women: A randomized clinical trial. *JAMA Netw Open* 2024; 7: e241784.
- 436 25. Center for Outcomes Research and economic evaluation for health, National Institute of
- Public Health, 2024. *Core to Evidence-Based Health*, Policy [cited 2024 Jun 7].
- 438 Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance
- 439 Medical Council. Available from:
- https://c2h.niph.go.jp/tools/guideline/guideline_en_2024.pdf.
- 26. Shiroiwa T, Noto S, Fukuda T. Japanese population norms of EQ-5D-5L and health
- 442 utilities index Mark 3: disutility catalog by disease and symptom in community settings.
- 443 *Value Health* 2021; 24: 1193–202.
- 444 27. Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive
- bladder symptoms on health-related quality of life, anxiety, depression, and treatment
- seeking in the United States: results from EpiLUTS. *Urology* 2012; 80: 90–6.
- 28. Omae K, Kurita N, Takeshima T, et al. Significance of overactive bladder as a predictor
- of falls in community dwelling older adults: 1-year followup of the Sukagawa study. J
- 449 *Urol* 2021; 205: 219–25.
- 450 29. Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic
- evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting
- guidance for health economic evaluations. *Pharmacoeconomics* 2022; 40: 601–9.

30. Funada S, Kawaguchi T, Terada N, *et al.* Cross-sectional epidemiological analysis of the
Nagahama study for correlates of overactive bladder: genetic and environmental
considerations. *J Urol* 2018; 199: 774–8.

Variables	Category	n	%	
Age	Mean (SD)	73.2	(5.3)	
	Median [IQR]	75	[68–77]	
Sex	Male	516	51.9	
BMI	Mean (SD)	22.6	(3.4)	
	Median [IQR]	22.3	[20.5–24.3]	
Educational attainment	College graduate or more	557	56.0	
Equivalent household income	Lower half	409	41.2	
	Upper half	360	36.2	
	Decline to answer	225	22.6	
Smoking status	Never	477	48.0	
	Past	410	41.3	
	Current	107	10.8	
Alcohol consumption	Never	246	24.8	
	Past	229	23.0	
	Current	519	52.2	
Presence of comorbidities	Hypertension	486	48.9	
	Dyslipidemia	407	41.0	
	Diabetes	166	16.7	
	Low back pain	566	56.9	
	Ischemic heart disease	91	9.2	
	Stroke	63	6.3	
	Chronic kidney disease	36	3.6	
	Stress urinary incontinence	114	11.5	
	Depression	50	5.0	
	Other psychiatric disorders	44	4.4	
OABSS	Mean (SD)	2.7	(2.2)	
	Median [IQR]	2	[1–4]	
Health utility value	Mean (SD)	0.90	(0.11)	
	Median [IQR]	0.89	[0.83-1]	
EQ-VAS score	Mean (SD)	75.2	(17.6)	
	Median [IQR]	80	[70–88]	

Note. BMI, body mass index; EQ VAS, EuroQol Visual Analogue Scale; IQR, interquartile range; LUTS, lower urinary tract symptom; OABSS, Overactive Bladder Symptom Scale; SD, standard deviation.

459

Table 2 Prevalence of OAB and utility values among overall respondents

OAB severity [*]	n (%)	Mean utility value (SD)	Median utility value [IQR]
Non-OAB	836 (84.1)	0.913 (0.105)	0.894 [0.867–1]
Any OAB	158 (15.9)	0.855 (0.145)	0.885 [0.784–1]
Mild OAB	71 (7.1)	0.874 (0.131)	0.895 [0.823–1]
Moderate-to-severe OAB	87 (8.8)	0.840 (0.155)	0.844 [0.759–1]

Note. IQR, interquartile range; OAB, overactive bladder; SD, standard deviation.

^{*}Mild OAB is defined as domain 3 (urgency) of overactive bladder symptom score (OABSS)≥2 and total score of 3≤OABSS≤5, and moderate-to-severe OAB is defined as domain 3 of OABSS≥2 and total score of 6≤OABSS≤15.

Table 3 Results of multivariate linear regression models in the main and sensitivity analyses

Variables	Category	$oldsymbol{eta}^*$	SE	95% CI	<i>p</i> -value	p for trend			
Main analysis (outcome measure: EQ-5D-5L)									
Presence or absence of OAB									
	Non-OAB	Non-OAB Reference			Not applicable				
	Any OAB	-0.0472	0.0098	-0.0664 to -0.0279	< 0.001	Not applicable			
Based on OAB severity									
	Non-OAB			Reference					
	Mild OAB	-0.0334	0.0136	-0.0602 to -0.0066	0.014	< 0.001			
	Moderate-to-severe OAB	-0.0591	0.0129	-0.0844 to -0.0339	< 0.001				
	Sensitivity analysis (outcome me	asure: EQ-	VAS)					
Presence or absence of OAB									
	Non-OAB	Non-OAB Reference			Not applicable				
	Any OAB	-5.42	1.55	−8.47 to −2.37	0.001	Not applicable			
Based on OAB severity									
	Non-OAB			Reference					
	Mild OAB	-4.36	2.16	-8.60 to -0.12	0.044	< 0.001			
	Moderate-to-severe OAB	-6.26	2.04	-10.26 to -2.27	0.002				

Note. EQ-5D-5L, the 5-level EuroQoL 5 dimensions version; EQ VAS, EuroQol Visual Analogue Scale; CI, confidence interval; OAB, overactive bladder; SE, standard error.

^{*}Adjusted for age, sex, body mass index, educational attainment, equivalent household income, smoking status, alcohol consumption, and presence of comorbidities (hypertension, dyslipidemia, diabetes, low back pain, ischemic heart disease, stroke, chronic kidney disease, stress urinary incontinence, depression, and other psychiatric disorders).

Figure legends

Figure 1 Flow diagram of this study

Figure 2 Results of multivariate linear regression models in the subgroup analyses

*Adjusted for age, sex, body mass index, educational attainment, equivalent household income,

smoking status, alcohol consumption, and presence of comorbidities (hypertension, dyslipidemia,

diabetes, low back pain, ischemic heart disease, stroke, chronic kidney disease, stress urinary

incontinence, depression, and other psychiatric disorders).

Abbreviations: CI, confidence interval; OAB, overactive bladder.

Figure 3 Results of multivariate linear regression models in the exploratory analyses

*Adjusted for age, sex, body mass index, educational attainment, equivalent household income,

smoking status, alcohol consumption, and presence of comorbidities (hypertension, dyslipidemia,

diabetes, low back pain, ischemic heart disease, stroke, chronic kidney disease, stress urinary

incontinence, depression, and other psychiatric disorders).

Abbreviations: CI, confidence interval; OABSS, overactive bladder symptom score.

Overall respondents

$$n = 1,099$$

Excluded: Preferred not to answer ...

Comorbidities, n = 67

Body mass index, n = 38

Study participants

n = 994



